Krystal Biotech

Yahoo Finance • 22 days ago

Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop

Key Points New York City-based S Squared Capital increased its Ambarella holding by 35,000 shares in the third quarter. The overall value of the position increased by about $4.8 million. As of quarter-end, the fund reported holding 153,55... Full story

Yahoo Finance • 22 days ago

Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm?

Key Points New York City-based S Squared Technology increased its position in IPG Photonics Corporation by 45,050 shares in the third quarter. The overall value of the position rose by about $4.4 million from the previous period. At quart... Full story

Yahoo Finance • 30 days ago

Krystal Biotech And 2 Other Growth Stocks Insiders Are Betting On

As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are closely watching growth companies with high insider ownership. In this environment, stocks like Krystal Biotech and... Full story

Yahoo Finance • last month

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S.... Full story

Yahoo Finance • 2 months ago

Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT

Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best gene-editing stocks to buy according to hedge funds. On November 5, Evercore ISI’s Gavin Clark-Gartner affirmed a Buy rating on Krystal Biotech, Inc. (NASDAQ:KRYS) stock and set a pric... Full story

Yahoo Finance • 3 months ago

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

Krystal Biotech, Inc. PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to th... Full story

Yahoo Finance • 3 months ago

Stocks of possible M&A targets have been crushing the market. Goldman says these 6 are the most likely to get bought.

Mergers and acquisitions activity has surged in 2025, with a 29% increase in deal value. Goldman Sachs predicts another 15% rise in M&A deals in 2026, boosting candidate valuations. It flagged a list of firms it sees as M&A targets. Here a... Full story

Yahoo Finance • 4 months ago

Krystal Biotech gets expanded FDA approval for Vyjuvek

[Male Medical Researcher] FatCamera/iStock via Getty Images Krystal Biotech (NASDAQ:KRYS [https://seekingalpha.com/symbol/KRYS]) announced that the FDA has approved an updated label for its gene therapy, Vyjuvek (beremagene geperpavec).... Full story

Yahoo Finance • 4 months ago

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that th... Full story

Yahoo Finance • 5 months ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy... Full story

Yahoo Finance • 5 months ago

Krystal Biotech price target lowered to $182 from $192 at BofA

BofA analyst Alec Stranahan lowered the firm’s price target on Krystal Biotech (KRYS) to $182 from $192 and keeps a Buy rating on the shares. While there were some positives from the Q2 report, the firm expects investors will be concerned... Full story

Yahoo Finance • 5 months ago

KRYSTAL BIOTECH INC (NASDAQ:KRYS) Q2 2025 Earnings Beat Estimates as VYJUVEK Drives Strong Revenue Growth

KRYSTAL BIOTECH INC (NASDAQ:KRYS [https://www.chartmill.com/stock/quote/KRYS]) reported second-quarter 2025 financial results, with revenue and earnings per share (EPS) surpassing analyst expectations. The company’s performance, particular... Full story

Yahoo Finance • 5 months ago

Krystal Biotech, Inc. Q2 Profit Advances, But Misses Estimates

(RTTNews) - Krystal Biotech, Inc. (KRYS) released earnings for its second quarter that Increases, from the same period last year but missed the Street estimates. The company's bottom line totaled $38.33 million, or $1.29 per share. This... Full story

Yahoo Finance • 5 months ago

Krystal Biotech GAAP EPS of $1.29 beats by $0.16, revenue of $96.04M beats by $4.08M

* Krystal Biotech press release [https://seekingalpha.com/pr/20187226-krystal-biotech-announces-second-quarter-2025-financial-and-operating-results] (NASDAQ:KRYS [https://seekingalpha.com/symbol/KRYS]): Q2 GAAP EPS of $1.29 beats by $0.1... Full story

Yahoo Finance • 6 months ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune... Full story

Yahoo Finance • 6 months ago

Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock

Suma Krishnan, a Director and President, R&D at Krystal Biotech , Inc. (NASDAQ:KRYS), sold a total of $5.39 million in company stock between July 14 and July 16, 2025. The sales, executed under a pre-arranged 10b5-1 trading plan, involved... Full story

Yahoo Finance • 6 months ago

Krishnan Krish S, Krystal Biotech CEO, sells $5.39 million in stock

Krystal Biotech (NASDAQ:KRYS), a $4.3 billion biotechnology company with impressive gross profit margins of 93.2%, reported insider selling activity. President and CEO Krishnan Krish S, along with his spouse, sold shares of common stock b... Full story

Yahoo Finance • 6 months ago

Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK

PITTSBURGH - Krystal Biotech, Inc. (NASDAQ:KRYS), a $4.1 billion biotech company with impressive 93% gross profit margins according to InvestingPro data, has dosed the first patient in its Phase 1/2 clinical trial evaluating KB801, an inve... Full story

Yahoo Finance • 6 months ago

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH, July 09, 2025 (GLOBE NEWS... Full story

Yahoo Finance • 6 months ago

Is Venezuela about to lose Citgo, its most prized foreign asset?

By Marianna Parraga HOUSTON (Reuters) -A U.S. court has received last-minute improved bids in a auction of shares in the parent of Venezuela-owned Citgo Petroleum from at least three consortia, potentially raising the price tag for the se... Full story